Cancer Genetics (CGIX) Receiving Positive Media Coverage, Study Finds

Press coverage about Cancer Genetics (NASDAQ:CGIX) has been trending positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cancer Genetics earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 44.4888143791935 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Cancer Genetics (NASDAQ:CGIX) remained flat at $$2.05 on Tuesday. The company’s stock had a trading volume of 63,400 shares, compared to its average volume of 209,040. Cancer Genetics has a 52-week low of $1.40 and a 52-week high of $5.30. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18. The firm has a market cap of $56.79, a P/E ratio of -2.50 and a beta of 1.10.

CGIX has been the topic of several research analyst reports. Maxim Group set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a research report on Wednesday, December 13th. HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a research report on Wednesday, November 29th. Zacks Investment Research downgraded Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, ValuEngine downgraded Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.56.

In other news, Director John Pappajohn purchased 150,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were acquired at an average price of $1.86 per share, with a total value of $279,000.00. Following the transaction, the director now owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 21.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Cancer Genetics (CGIX) Receiving Positive Media Coverage, Study Finds” was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply